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IMPORTANCE The transition from pediatric to adult health care is a vulnerable time for
patients with chronic conditions. We need to better understand the factors affecting the
health of kidney transplant recipients during this transition.
OBJECTIVE To determine the age at which renal transplant recipients are at greatest risk for
graft loss.
DESIGN, SETTING, AND PARTICIPANTS We performed a retrospective analysis of 168 809 first
kidney-only transplant events from October 1987 through October 2010, in recipients up to
age 55 years as reported by the Organ Procurement Transplantation Network Standard
Transplant Analysis and Research Database. Recipient age at transplant was the primary
predictor studied. Confounder and effect modifier covariates were identified and studied
using Cox proportional hazard models.
EXPOSURE Kidney-only transplant.
MAIN OUTCOMES AND MEASURES Patient and renal graft survival, along with death-censored
and non–death-censored information.
RESULTS A total of 168 809 renal transplant events met the inclusion criteria. Recipients who
received their first kidney transplant at age 14 to 16 years were at the highest risk of graft loss,
with inferior outcomes starting at 1 and amplifying at 3, 5, and 10 years after transplant. Black
adolescents were at disproportionately high risk of graft failure. The variables that had
significant interaction with recipient age were donor type (deceased vs living) and insurance
type (government vs private). Among 14-year-old recipients, the risk of death was 175%
greater in the deceased donor–government insurance group vs the living donor–private
insurance group (hazard ratio, 0.92 [95% CI, 0.90-0.94] vs 0.34 [95% CI, 0.33-0.36]),
whereas patient survival rates in the living donor–government insurance and deceased
donor–private insurance groups were nearly identical (hazard ratio, 0.61 [95% CI, 0.58-0.63]
vs 0.54 [95% CI, 0.51-0.56]).
CONCLUSIONS AND RELEVANCE Recipients aged 14 to 16 years have the greatest risk of kidney
allograft failure. Black adolescents and those with government insurance are at even higher
risk. Private insurance reduces risk of death across all ages. Comprehensive programs are
needed for adolescents, especially for those at greater risk, to reduce graft loss during the
transition from adolescence to adulthood.
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R enal failure is the most common end-stage organ diseasein children and adolescents. With advances in medicaland surgical care, the 10-year survival for adolescent-
onsetend-stagerenaldiseaseis80%.1 Investigatorshavereported
that compared with younger recipients, adolescents have bet-
ter graft survival at 1 year but have greater graft losses within a
decade of transplant. Graft losses by adolescents are partly due
to physiologic and/or immunologic alterations with age, but psy-
chological and sociological factors play a large role, especially in
affecting adherence to medication.2-4 These challenges intensify
as adolescents transfer to adult-centered medical care.5
The existing literature does not adequately describe the risks
of graft failure among renal transplant recipients by age at the
time of transplant. Studies have used various arbitrary age
groupings with differing results.6,7 For example, the Organ Pro-
curement and Transplantation Network (OPTN) data, as evalu-
ated in the Scientific Registry for Transplant Recipients (SRTR)
Annual Report, stratifies graft and patient survival outcomes by
the following age range categories: less than 1, 1 to 5, 6 to 11, 12
to 17, 18 to 34, 35 to 49, 50 to 64, and older than 65 years.8 Thus,
the average outcomes within the large age spans of these groups,
especially in the pediatric recipients, may be concealing impor-
tant information that could define particularly high-risk popu-
lations. We used this OPTN database to define relative risks of
graft and patient survival by age at transplant, adjusted for re-
cipient and donor characteristics.
Methods
Study Population
The OPTN-SRTR contains data on the kidney transplant re-
cipient and donor information from all living and deceased do-
nors in the United States. We investigated all recipients who
were not older than 55 years of age, with no transplant his-
tory, who received a primary renal graft from a living or stan-
dard criteria deceased donor during the period October 1987
through October 2010. Race was indicated by self-report. Re-
cipients were excluded if the transplant date was missing or
if they had received organs labeled as coming from donation
after cardiac death and extended criteria donors, hepatitis
C–positive donors, or non–US citizen donors.
A total of 168 809 renal transplant events met the inclu-
sion criteria for analysis (eFigure 1 in Supplement). Time-to-
event analysis was conducted for death-censored and non–
death-censored graft failure and for patient death. Graft survival
was estimated for both death-censored and non–death-
censored graft failure. Patients who died with a functioning graft
were considered a graft loss in the latter group. Death-
censored results favor outcomes in older recipients, who tend
to die with a functioning graft, compared with non–death-
censored outcomes, which favor younger recipients because of
the larger number of deaths in the older group. The study was
approved by the University of Florida institutional review board.
Statistical Analysis
Categorical data are reported as frequencies and percent-
ages, and continuous variables are reported with mean and
standard deviation. The primary analyses consisted of an ad-
justed Cox proportional hazard regression for all 3 end points
(death-censored and non–death-censored graft failure and pa-
tient death). All variables in the data set with plausible effect
on outcome were evaluated. Continuous variables entered into
the model were checked to determine whether they were lin-
ear in the log-hazard, using the methods of fractional polyno-
mials. The proportional hazard assumption was tested in the
final model by determining whether the graph of the scaled
Schoenfeld residuals over event time was horizontal. Age at
transplant was entered into the model as a quartic expression
(ie, age, age2, age3, age4) because we expect that the out-
comes when graphed over age at transplant would have 3
changes in concavity. Age at transplant for the relative hazard
graphs was centered at 18 years. Graft half-life and median graft
survival were estimated from the Cox proportional hazard re-
gression model. The final curves of graft half-life were
smoothed using fractional polynomials. The 95% confidence
intervals were omitted from the figures because they only
thicken the graphed line as a result of large sample size.
Because the study’s goal was to identify the role of age at
transplant in graft and/or patient survival, we used a risk fac-
tor modeling approach to determine which covariates to add to
the Cox proportional hazard regression model. We included only
those covariates that acted either as a confounder or as an ef-
fect modifier. A confounder was identified when its addition to
the model changed the hazard ratio (HR) associated with the age
at transplant by more than 10% in either direction. A covariate
that had a statistically significant interaction (P ≤ .05) with age
at transplant was considered an effect modifier. The figures
across age at transplant are produced from the adjusted Cox pro-
portional hazard models, where the covariates held at either
their median (if a continuous variable) or at their most preva-
lent level (if a categorical variable). Analyses were run using
Stata, version 11.2 (StataCorp).
Results
The study population characteristics depicted in the Table in-
clude the recipients’ sex, race, and insurance type and the do-
nors’ living vs deceased status, sex, and health, and their com-
bined HLA match information. Of the 168 809 first kidney
transplants evaluated, there were 46 854 graft failures prior to
patient death (27.8%) and 17 826 deaths with a functioning graft
(10.6%), for a total of 46 854 death-censored graft failures and
64 680 non–death-censored graft failures. During the fol-
low-up period, 15.2% of the recipients died, and 69.3% had a
functioning graft at the time of death. The Kaplan-Meier me-
dian patient survival time was 21.2 years. More patients re-
ceived transplants toward the later years of the study period;
therefore, the median (mean) follow-up time was 5.0 (6.0) years.
Two variables had significant interaction with age at trans-
plant: donor type (living vs deceased donor) and the recipi-
ent’s insurance type at the time of transplant (private vs gov-
ernment). From these 2 variables, it is possible to construct 4
unique groups. The proportional distribution of the 4 groups
in the sample is as follows: living donor–government insur-
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ance, 21.0%; living donor–private insurance, 22.1%; deceased
donor–government insurance, 44.8%; and deceased donor–
private insurance, 12.1%. See eFigure 2 in the Supplement for
a complete list of variables. Unless otherwise specified, the “re-
cipient age at transplant” graphs were produced using the fol-
lowing covariate pattern: recipient’s race was white, recipi-
ent’s sex was male, recipient’s and donor’s histories were
negative for diabetes mellitus and hypertension, HLA mis-
match level was 3, and donor age was 36 years.
Graft Survival Confounders and Effect Modifiers
In the Supplement, eTables 1A and 1B illustrate our 4 effect modi-
fiers in the Cox proportional hazard model, as well as the other
potential confounder variables (recipient and donor character-
istics) that were candidates for the regression model. Because
donor and insurance type significantly interact with age, the HRs
for the 4 groups created by these 2 variables are different for each
age and are presented graphically (Figure 1). Age was a strong
predictor of death-censored and non–death-censored graft fail-
ure for all 4 groups. Being a black recipient conveyed the great-
est risk of graft failure (HR, 1.72 death censored [95% CI, 1.68-
1.75]; HR, 1.43 non–death censored [95% CI, 1.41-1.45] vs white
recipients; both P < .001). Diabetes mellitus in the recipient was
associated with the next highest risk for non–death-censored
graft failure, with donor diabetes mellitus hastening both death-
censored and non–death-censored graft failure.
The degree of HLA mismatch resulted in increased risk of
graft failure in both death-censored and non–death-censored
models (HR, 1.08 [95% CI, 1.07-1.08] and HR, 1.05 [95% CI, 1.05-
1.06], respectively; both P < .001) per unit increase in the de-
gree of mismatch (eFigure 3 in Supplement). Increasing age of
the donor predicted increased risk of graft loss in the death-
censored and non–death-censored models. Donor hyperten-
sion was associated with increased graft failure in the death-
censored model (HR, 1.05 [95% CI, 1.01-1.09]; P < .001).
Using age at transplant as the risk factor, we determined a
decreasing relative hazard of graft failure, finding the highest
risk in the deceased donor–government insurance group, sec-
ond highest risk in the deceased donor–private insurance group,
third in the living donor–government insurance group, and the
lowest risk in the living donor–private insurance group. In the
death-censored analysis, this order was consistent from in-
fancy to age 55 years. In the non–death-censored analysis, the
deceased donor–private insurance group and the living donor–
government insurance groups merged at approximately age 40
through 55 years.
Patient Survival Confounders
In the Supplement, eTable 1C illustrates the Cox proportional
hazard model of time to patient death. There were no effect
modifiers of age, and thus the HR of each confounder is inde-
pendent of age. Age of the recipient at transplant was strongly
predictive of death in the quartic expression. Using deceased
donor–government insurance as the reference group, all other
groups had improved patient survival, with living donor–
government insurance second worst (HR, 0.66 [95% CI, 0.64-
0.68]; P < .001), deceased donor–private insurance next (HR,
0.63 [95% CI, 0.62-0.66]; P < .001), and living donor–private in-
surance best (HR, 0.42 [95% CI, 0.40-0.43]; P < .001). The risk
for patient death in the deceased donor–government insur-
ance group increased greatly above the other groups as recipi-
ent age exceeded 25 years.
With white race as reference, black recipients had lower
rates of posttransplant survival (HR, 1.06 [95% CI, 1.04-1.09];
Table. Recipient and Donor Characteristics
Characteristics and Events
Summary Statistics
(n = 168 809)
Recipients
Male sex, No. (%) 100 031 (59.3)
Age at transplant, mean (SD), y 37.7 (12.6)
Race, No. (%)
White 95 433 (56.5)
Black 40 363 (23.9)
Hispanic 22 758 (13.5)
Other 10 255 (6.1)
Insurance at transplant, No. (%)
Government 111 047 (65.8)
Private 57 762 (34.2)
Diabetes mellitus, No. (%) 26 240 (15.5)
Hypertension, No. (%) 88 032 (52.1)




(graft failure or death), No. (%)
64 680 (38.2)
Graft survival, median (95% CI), y 10.6 (10.5-10.7)
Deaths, No. (%) 25 714 (15.2)
Survival, median (95% CI), y 21.2 (21.0-21.8)
Death with a functioning graft, No. (%) 17 826 (10.6)
Death-censored events
(graft failure prior to death), No. (%)
46 854 (27.8)
Graft survival, median (95% CI), y 13.6 (13.5-13.8)
Donors
Male sex, No. (%) 90 632 (53.7)
Type, No. (%)
Living 72 731 (43.1)
Deceased 96 078 (56.9)
Diabetes mellitus, No. (%) 2104 (1.2)
Age, mean (SD), y 34.4 (14.0)
Serum creatinine level, median (IQR) 0.9 (0.7-1.1)
Hypertension, No. (%) 8784 (5.2)
Recipient and donor HLA information
HLA mismatch levela
0 17 533 (10.5)
1 8838 (5.3)
2 21 369 (12.8)
3 37 859 (22.7)
4 33 175 (19.9)
5 32 277 (19.4)
6 15 717 (9.4)
Abbreviations: IQR, interquartile range; PRA, panel reactive antibody.
a HLA mismatch level ranges from 0 (6-antigen match) to 6 (complete
mismatch). Mismatch level data were missing for 2041 patients (n = 168 809).
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P < .001), whereas recipients of Hispanic and other races had
greater survival than white recipients (HR, 0.72 [95% CI, 0.69-
0.74] and HR, 0.72 [95% CI, 0.68-0.75]; P < .001 for each). Re-
cipient characteristics associated with lower survival in-
cluded male sex (HR, 1.11 [95% CI, 1.09-1.13]), having diabetes
mellitus (HR, 1.69 [95% CI, 1.65-1.73]), increasing HLA mis-
match (HR, 1.03 for 1 unit increase [95% CI, 1.02-1.04]), and age
of donor (HR, 1.01 for 1 year increase [95% CI, 1.00-1.01]) (all
P<.001). Recipient hypertension (HR, 0.85 [95% CI, 0.83-
0.86]) and donor hypertension (HR, 0.94 [95% CI, 0.90-0.98])
each correlated with lower recipient risk of death.
Graft and Patient Survival by Recipient Age at Transplant
Adolescent recipients aged 14 to 16 years had the highest risk
of any age group of graft loss (death censored and non–death
censored) starting at 1 year after transplant, and amplifying at
3, 5, and 10 years after transplant (Figure 2). This is despite hav-
ing the best patient survival (Figure 3). Black adolescents are
at a disproportionate risk of graft failure at these time points
compared with nonblack adolescents (Figure 4). Black ado-
lescents 14 to 16 years of age had lower rates of graft survival
in their highest performing group, living donor–private insur-
ance (0.43 [reported as a proportion] death censored [95% CI,
0.36-0.49], 0.42 non–death censored [95% CI, 0.36-0.48]), than
the lowest performing nonblack group, deceased donor–
government insurance (0.49 death censored [95% CI, 0.42-
0.55], 0.42 non–death censored [95% CI, 0.36-0.48]). The 10-
year graft survival for 14-year-old nonblack recipients in the
living donor–private insurance group (0.62 death censored [95%
CI, 0.57-0.67], 0.58 non–death censored [95% CI, 0.52-0.64])
was more than twice that for black recipients the same age in
the deceased donor–government insurance group (0.28 death
censored [95% CI, 0.21-0.34], 0.26 non–death censored [95%
CI, 0.21-0.32]; data not shown).
At 10 years after transplant, black recipients in the de-
ceased donor–government insurance group who received a
transplant when they were 10 years old displayed a 0.28 (95%
CI, 0.21-0.34) death-censored graft survival rate and 0.26 (95%
CI, 0.21-0.32) non–death-censored graft survival rate, com-
pared with the nonblack recipients at 0.49 (95% CI, 0.42-
0.55) and 0.42 (95% CI, 0.36-0.48), respectively. This differ-
ence was 75% and 65% between the racial groups. The same
comparisons at recipient age 40 years had smaller differ-
ences of 39% and 19% between the racial groups.
Although living donor recipients had better rates of graft
survival than deceased donor recipients within insurance
groups, there were surprisingly similar outcomes between the
living donor–government insurance and the deceased donor–
private insurance groups. This can be most easily appreci-
ated in Figure 1, which shows the overall HR of death-
censored and non–death-censored graft failure. Graft loss in
the living donor–private insurance adolescent group was ap-
proximately 50% lower than in the deceased donor–
government insurance group over all transplant ages. Among
14-year-old recipients, the risk of death was 175% greater in the
deceased donor–government insurance group vs the living do-
nor–private insurance group (HR, 0.92 [95% CI, 0.90-0.94] vs
0.34 [95% CI, 0.33-0.36]), whereas the risk of death was simi-
lar between the living donor–government insurance and de-
ceased donor–private insurance groups (HR, 0.61 [95% CI, 0.58-
Figure 1. Graft Failure Relative Hazard According to Age at Transplant, Centered at 18 Years
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A, Death censored; B, non–death
censored. Graphs were produced
using the following covariate pattern:
race was white, sex was male,
recipient’s and donor’s histories were
negative for diabetes mellitus and
hypertension, HLA mismatch level
was 3, and donor age was 36 years.
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0.63] vs 0.54 [95% CI, 0.51-0.56]) (Figure 3). Recipients with
private insurance in all age groups had a lower relative hazard
risk of death (for both living and deceased donors) compared
with those with government insurance (Figure 3).
Graft Half-life
Figure 5 illustrates the graft half-life, in which the death-
censored results show similar half-lives for the living donor–
government insurance vs the deceased donor–private insur-
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Comparison of death-censored (A) and non–death-censored (B) graft survival
across the 4 categories of recipients at 1, 3, 5, and 10 years after transplant.
Death-censored analysis results favor graft outcomes in older recipients, who
tend to die with a functioning graft, compared with non–death-censored
outcomes, which favor younger recipients because of the larger number of
deaths in the older group. Graphs were produced using the following covariate
pattern: race was white, sex was male, recipient’s and donor’s histories were
negative for diabetes mellitus and hypertension, HLA mismatch level was 3, and
donor age was 36 years.
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ance groups. For children between 5 and 10 years of age, these
outcomes are nearly identical. Recipients in the living donor–
private insurance group have approximately a 4-year in-
crease in graft half-life compared with those in the living donor–
government insurance group and more than 8 years greater
than that of a 40-year-old recipient in the deceased donor–
government insurance group. For the non–death-censored
curve, the most noticeable difference is the merging of the liv-
ing donor–government insurance and the deceased donor–
private insurance curves at just over age 40 years.
Discussion
This study uses the OPTN database to determine longitudinal
outcomes of recipients based on their age at transplant in 1-year
increments. Adolescents between 14 and 16 years of age have
worse longitudinal outcomes during a 10-year period than other
age cohorts. The realization that this age group is at an in-
creased risk of graft loss as they are becoming young adults
should prompt providers to give specialized care and atten-
tion to these adolescents in the transition from pediatric to
adult-focused care. Implementing a structured health care tran-
sition preparation program from pediatric to adult-centered
care in transplant centers may improve outcomes.
Our study revealed better outcomes for recipients of trans-
plants from living donors over those who received deceased
donor grafts and private over government insurance cover-
age. However, patients with private insurance at the time of a
deceased donor transplant did almost as well as those who re-
ceived a graft from a living donor but had government insur-
ance. Black adolescents had disproportionately worse out-
comes compared with nonblack recipients across all donor and
insurance groups. These outcomes may be related to immu-
nological, cultural, educational, learning, and/or economic dif-
ferences that translate into substantial effects on short-term
and long-term graft and/or patient survival. Importantly, oth-
ers have found that whereas dialysis survival for older black
patients is superior to that for white patients, black patients
younger than 50 years have a higher mortality than white pa-
tients when both dialysis survival and renal transplant out-
comes are considered in a competing risk model.9
Foster et al10 performed a recent review of the OPTN da-
tabase looking at recipients up to age 40 years. These inves-
tigators concentrated on the age at which recipients lost their
renal grafts, with early failures excluded; they found the high-
est rate of graft loss in the 19-year-old recipients. They per-
formed the age-at-transplant analysis in varying age groups:
0 to 4, 5 to 9, 10 to 12, 13 to 16, 17 to 20, 21 to 24, 25 to 29, 30 to
34, and 35 to 39 years. They did not present the age-at-
transplant data as an overall risk of graft failure but examined
graft failure rate per year after transplant by age groups; thus,
we cannot easily compare their results to ours.
Levine et al7 used OPTN data and divided the recipients
into age groups of 0 to 14, 15 to 18, 19 to 25, 26 to 40, 41 to 55,
56 to 70, and older than 70 years. These investigators showed
that the adolescent recipients in the 15- to 18-year-old age group
had the worst survival of allografts from “ideal deceased do-
nors” (age <35 years, serum creatinine level <1.5 mg/dL [to con-
vert to micromoles per liter, multiply by 88.4], and no hyper-
tension, diabetes mellitus, or hepatitis C) compared with most
age groups, except for those older than 70 years. Ekstrand et
al11 examined those who received a renal transplant before age
18 years but were now older than 18 years, a group they termed
transitional recipients. These authors showed that transi-
tional recipients had increased allograft failure compared with
those who were younger than 18 years or those who received
a transplant when they were older than 18 years. This differ-
ence was present 3 years after transplant (21% graft failure vs
18% in adults and 11% in children). Keith et al12 also demon-
strated that the 10- to 19-year-old age group in the United Net-
work for Organ Sharing database had the worst long-term al-
lograft survival, equivalent to those older than 60 years when
all recipients were grouped by decade of life. In our study, year
of transplant was neither an effect modifier nor a confounder
of the relationship between age at transplant and graft failure
or age at transplant and patient survival; therefore, the OPTN
kidney allocation policy change to “Pediatric Share 35” in Sep-
tember 2005, in which organs from donors younger than 35
years are preferentially offered to pediatric recipients, did not
change the relationships developed in the overall model.
Preparation for the health care transition from pediatric
to adult-focused care is gaining interest as a target for improve-
ment in health outcomes. The American Academy of Pediat-
rics states,13(p1304)
The goal of transition in health care for young adults with
special health care needs is to maximize lifelong functioning and
potential through the provision of high-quality developmen-
tally appropriate health care services that continue uninter-
rupted as the individual moves from adolescence to adulthood.
Despite published medical societies’ consensus statements
since 2002 stating the importance of facilitating health care
transition preparation for youth with special health care needs,
little improvement has been realized.13-15 The effects of the 2011
Figure 3. Relative Hazard of Death According to Age at Transplant,
Centered at 18 Years
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Graphs were produced using the following covariate pattern: race was white,
sex was male, recipient’s and donor’s histories were negative for diabetes
mellitus and hypertension, HLA mismatch level was 3, and donor age was
36 years.
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consensus statements by the International Society of Nephrol-
ogy and International Pediatric Nephrology Association16 re-
main to be seen.
In transplantation, 18 years of age is usually the distinc-
tion between adolescence and adulthood. It has been sug-
gested that those undergoing transplant before age 18 years are
usually in a pediatric-oriented environment whereas those in
their twenties begin in an environment where most patients
are significantly older. Certainly, maturation and complete
brain development occur after the age of 18 years, and the con-
cept of emerging adulthood suggests that in modern society,
adulthood is often delayed until the late twenties. This is mir-
rored in our outcomes, in which 12-month mortality steadily
decreases as patients age from 20 to 30 years. For this reason,
there has been a movement by pediatric specialists including
cardiologists,17 nephrologists,14 pulmonologists,18 and gas-
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A, Death censored; B, non–death censored. Graphs were produced using the
following covariate pattern: race was white, sex was male, recipient’s and
donor’s histories were negative for diabetes mellitus and hypertension, HLA
mismatch level was 3, and donor age was 36 years.
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troenterologists and hepatologists19,20 to design organized and
effective programs that allow patients to optimize transition
from pediatric to adult-centered care in an effort to avoid the
increased morbidity and mortality associated with young adult-
hood.
There is no current consensus on how to implement or
measure this health care transition preparation or what suc-
cessful outcomes of this process would be; however, some cen-
ters have published methods and are currently validating strat-
egies to improve outcomes as patients with chronic kidney
disease transition to adulthood.21 The transition process in-
volves the patients, families, pediatric and adult-focused health
care providers, and interdisciplinary collaboration. There is a
growing literature in asthma, rheumatoid arthritis, and dia-
betes mellitus that notes that chronic care models that incor-
porate and promote disease self-management have im-
proved outcomes compared with those lacking such
self-management.22 The University of North Carolina STARx
(Self-management and Transition to Adulthood With Treat-
ment) Program has designed tools to measure transition and
developed culturally appropriate and literacy-appropriate in-
terventions, while determining self-management, adher-
ence, and graft and patient survival, in collaboration with other
institutions.23
Our study clearly displays an increased risk of graft loss
for recipients aged 14 to 16 years and a poor 10-year graft sur-
vival in this US cohort. This health care disparity is amplified
among black adolescents, particularly among those with gov-
ernment insurance. In the United States, an estimated 4000
kidney transplant recipients and 2000 patients receiving di-
alysis are in this critical transition age range with health-
related challenges that include not only medical but also cog-
nitive, developmental, psychological, and socioeconomic
factors. In this country, dialysis care is covered by Medicare
for adults and minors with end-stage renal disease as long as
the adult—or the parent of a minor patient—contributed to
Medicare payroll tax for 40 work quarters, or the patient has
reached 65 years of age or is disabled. Medicare coverage con-
tinues for up to 36 months after transplant in regard to immu-
nosuppressive medications for patients younger than 65 years
who are no longer considered disabled. The loss of Medicare
coverage for immunosuppressive medications may play a role
in the morbidity and mortality described, but the impact of this
coverage loss was not available for our investigation. The liv-
ing donor recipient advantage that we noted may be in part re-
lated to (1) pretransplant events such as the selection of bet-
ter immunological matches from family members and the
higher quality of the donor organ, (2) peritransplant events such
as shorter ischemia times or optimal condition of the recipi-
ent at the time of surgery, and (3) posttransplant events such
as better immunological tolerance and possibly stronger fam-
ily support.
The timing of a patient’s transfer to adult-focused care
should be flexible and personalized on the basis of the readi-
ness of the patient.24 Preparation for health care transition may
help offset some of the disparities demonstrated by the ado-
lescent transplant recipients. Implementing health care tran-
sition preparation programs in both the pediatric and adult in-
ternal medicine settings could be a cost-effective solution to
this urgent, unmet need.
Figure 5. Graft Half-life (Median Survival) According to Age at Transplant
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A, Death censored; B, non–death
censored. Graphs were produced
using the following covariate pattern:
race was white, sex was male,
recipient’s and donor’s histories were
negative for diabetes mellitus and
hypertension, HLA mismatch level
was 3, and donor age was 36 years.
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